HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

NCT07570433 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

CMV Infection

Interventions

DRUG: 50% reduction in the dose of MPA
DRUG: Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus
DRUG: standard antiviral therapy along with maintenance of their initial immunosuppressive therapy.

Sponsor

Oriol Manuel

Collaborators

[object Object]
[object Object]
[object Object]